CY1123652T1 - Πολλαπλολειτουργικα μαγνητο-πολυμερικα νανοσυστηματα για ταχεια στοχευση, απομονωση, ανιχνευση και ταυτοχρονη απεικονιση των κυκλοφορουντων κυτταρων ογκων - Google Patents

Πολλαπλολειτουργικα μαγνητο-πολυμερικα νανοσυστηματα για ταχεια στοχευση, απομονωση, ανιχνευση και ταυτοχρονη απεικονιση των κυκλοφορουντων κυτταρων ογκων

Info

Publication number
CY1123652T1
CY1123652T1 CY20201101018T CY201101018T CY1123652T1 CY 1123652 T1 CY1123652 T1 CY 1123652T1 CY 20201101018 T CY20201101018 T CY 20201101018T CY 201101018 T CY201101018 T CY 201101018T CY 1123652 T1 CY1123652 T1 CY 1123652T1
Authority
CY
Cyprus
Prior art keywords
isolation
nanosystems
magneto
multifunctional
polymer
Prior art date
Application number
CY20201101018T
Other languages
English (en)
Inventor
Jayant Jagannath Khandare
Shashwat BANERJEE
Muralidhara Padigaru
Ganesh KHUTALE
Original Assignee
Actorius Innovations And Research Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actorius Innovations And Research Pvt. Ltd. filed Critical Actorius Innovations And Research Pvt. Ltd.
Publication of CY1123652T1 publication Critical patent/CY1123652T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Βιολειτουργικό πολλαπλοσυστατικό νανοσύστημα για συγκεκριμένη στόχευση, ταχεία απομόνωση και ταυτόχρονη απεικόνιση υψηλής διακριτικής ικανότητας των κυττάρων καρκίνων αποκαλύπτεται.
CY20201101018T 2015-02-19 2020-10-27 Πολλαπλολειτουργικα μαγνητο-πολυμερικα νανοσυστηματα για ταχεια στοχευση, απομονωση, ανιχνευση και ταυτοχρονη απεικονιση των κυκλοφορουντων κυτταρων ογκων CY1123652T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN538MU2015 2015-02-19
PCT/IB2016/050779 WO2016132265A2 (en) 2015-02-19 2016-02-15 Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells

Publications (1)

Publication Number Publication Date
CY1123652T1 true CY1123652T1 (el) 2022-03-24

Family

ID=56688724

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101018T CY1123652T1 (el) 2015-02-19 2020-10-27 Πολλαπλολειτουργικα μαγνητο-πολυμερικα νανοσυστηματα για ταχεια στοχευση, απομονωση, ανιχνευση και ταυτοχρονη απεικονιση των κυκλοφορουντων κυτταρων ογκων

Country Status (7)

Country Link
US (2) US20180024135A1 (el)
EP (1) EP3259598B1 (el)
CA (1) CA2976614A1 (el)
CY (1) CY1123652T1 (el)
ES (1) ES2828025T3 (el)
PL (1) PL3259598T3 (el)
WO (1) WO2016132265A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106824129B (zh) * 2017-02-15 2019-06-14 南昌航空大学 一种可分级回收Pb2+和4-NP的吸附剂的制备方法
EP3533472A1 (en) * 2018-03-02 2019-09-04 Universität Zürich Bioconjugates of antibodies and functionalized magnetic nanoparticles
CN109125725B (zh) * 2018-09-03 2021-04-02 浙江理工大学 一种具有磁靶向性的缓释可控光热-磁热-抗癌药物协同作用纳米微粒的制备方法
CN109682967B (zh) * 2018-12-17 2021-12-28 暨南大学 Pamam在制备用于免疫检测的试剂中的应用
CN109939080B (zh) * 2019-03-11 2021-03-09 陕西师范大学 基于共轭聚合物的热敏型载药纳米粒子及其制备方法
US11012035B2 (en) 2019-05-15 2021-05-18 Nxp Usa, Inc. Amplifier devices with input transient termination
US11082016B2 (en) 2019-05-15 2021-08-03 Nxp Usa, Inc. Amplifier devices with reflection absorption
CA3154234A1 (en) * 2019-10-14 2021-04-22 Jayant Jagannath Khandare Non-hemolytic compositions and methods of use for recovering disease causing toxic constituents in the blood
CN113189070B (zh) * 2021-04-28 2024-01-16 香港理工大学 一种纳米探针及其制备方法和应用、循环肿瘤细胞的miRNAs的检测系统
US20240159764A1 (en) * 2022-11-12 2024-05-16 OneCell Diagnostics, Inc. Compositions and methods for selective capture, purification, release and isolation of single cells
CN117607441B (zh) * 2024-01-23 2024-04-12 杭州华得森生物技术有限公司 一种循环肿瘤细胞trop-2免疫显色检测试剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333225B2 (en) 2006-12-08 2014-06-12 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
BR112013009008A2 (pt) * 2010-10-14 2017-10-17 Veridex Llc métodos e kits para a detecção de células circulantes de tumor em pacientes pancreáticos com o uso de reagentes de detecção de captura e de coquetel poliespecíficos
EP2530125A1 (en) * 2011-05-30 2012-12-05 Total SA Core-shell particles with catalytic activity

Also Published As

Publication number Publication date
US20230408525A1 (en) 2023-12-21
EP3259598B1 (en) 2020-07-29
US20180024135A1 (en) 2018-01-25
PL3259598T3 (pl) 2021-03-08
ES2828025T3 (es) 2021-05-25
EP3259598A4 (en) 2018-10-10
WO2016132265A2 (en) 2016-08-25
CA2976614A1 (en) 2016-08-25
WO2016132265A3 (en) 2017-11-23
EP3259598A2 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
CY1123652T1 (el) Πολλαπλολειτουργικα μαγνητο-πολυμερικα νανοσυστηματα για ταχεια στοχευση, απομονωση, ανιχνευση και ταυτοχρονη απεικονιση των κυκλοφορουντων κυτταρων ογκων
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
EP3286224A4 (en) Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP3397968A4 (en) INHIBITORS OF UREA PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) FOR IMAGING AND THERAPEUTIC TREATMENT
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
EP3100046A4 (en) Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CY1121722T1 (el) Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης
IL258378B (en) Inhibitors of 18f-labeled prostate-specific membrane antigen and their use as imaging agents for prostate cancer
EP3099821A4 (en) Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)
CL2018000616A1 (es) Dispositivos médicos internos con energía con ondas superficiales guiadas
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
EP3298172A4 (en) Determining risk of prostate cancer recurrence
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3277325T3 (da) Kombinationsimmunterapi for cancer
CL2017001172A1 (es) Anticuerpos anti-interleukin-33 y sus usos
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
TH178656B (th) องค์ประกอบเภสัชภัณฑ์สำหรับรักษามะเร็งและการเตรียมเภสัชภัณฑ์สำหรับ รักษามะเร็งที่มีองค์ประกอบเดียวกับส่วนผสมออกฤทธิ์
UA92824U (uk) Спосіб діагностики вогнищевих кісткових уражень у пацієнтів з онкологічними захворюваннями
TH1601005344A (th) ระบบและวิธีการตรวจสอบด้วยการฉายรังสีเป้าเคลื่อนผ่านไวแบบโหมดคู่